Company Looks to Protect and Provide Terpene Technology in Rapidly Expanding Cannabis Beverage Market
LAS VEGAS, March 5, 2019 /PRNewswire/ — Digipath, Inc. (OTCQB: DIGP), a service-oriented independent testing laboratory, data and media firm focused on the developing cannabis and hemp market, is pleased to announce that it has filed a United States provisional patent application for “A METHOD FOR AUGMENTING TERPENE PROFILES IN BEER AND OTHER BEVERAGES.”
Hops used in the production of beer contain terpenes, which are lost through the normal brewing process. Still, subtle undocumented effects may be left behind in the finished product. Hops cultivators and beer producers currently have no control over the levels of the various terpenes’ impact as imparted into the beer products through the use of hops. Just as cannabis is sold based on its THC content, hops tends to be sold based on its terpene content. This lack of control extends to the physiological effects, benefits or lack of benefits to the beer drinking consumers. Digipath’s technology gives brewers significant control and accountability for the finished product, allowing for accurate reporting, marketing, and customer satisfaction potentially across the entire cannabis-infused beverage category.
The filing comes at a time when major beverage companies are aggressively entering the Cannabis/Beverage space following a decline in beer sales in many areas after the introduction of legalized cannabis. According to a ten-year-long joint study, results showed a 13.8 percent drop in beer sales after cannabis legalization. Additionally, data confirms that sales of alcohol were, on average, fifteen percent lower in states with legalized cannabis. The same study also showed that cannabis and alcohol have a widely overlapping consumer base. ( Click here for the full story. )
“The underlying method detailed in this provisional patent can be applied to any individual terpene or combination of terpenes and can be used to augment any type of beverage including mimicking of a specific cannabis cultivar terpene profile,” stated Dr. Orser. “Terpenes are major components of plant derived essential oils used by humans for thousands of years, and they are abundant in unique combinations in hops. These terpenes can be used to distinguish hops cultivars from one another and many terpenes have documented physiological effects in mammals.”
We hope and expect our patents to be approved and to add this to our ever-growing portfolio of practical, monetizable cannabis technology,” added Dr. Orser.
About Digipath, Inc. &Digipath Labs, Inc.
Digipath, Inc. supports the cannabis industry’s best practices for reliable testing, data acquisition, cannabis education and training, and brings unbiased cannabis news coverage to the cannabis industry. Digipath Labs provides pharmaceutical-grade analysis and testing to the cannabis industry to ensure producers, consumers, and patients know exactly what is in the cannabis they ingest and to help maximize the quality of its client’s products through analysis, research, development, and standardization.
Digipath Investor Relations & Financial Media
Integrity Investor Relations
[email protected]
Toll Free: (888) 216-3595
www.IntegrityIR.com
Information about Forward-Looking Statements
This press release contains “forward-looking statements” that include information relating to future events. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the Company’s need for additional funding, the demand for the Company’s products, governmental regulation of the cannabis industry, the Company’s ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company’s liquidity and financial strength to support its growth, and other risks that may be detailed from time-to-time in the Company’s filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting Digipath, please refer to the Company’s recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
SOURCE Digipath, Inc.
